Springworks Therapeutics Inc.

Desmoid Tumours and Aggressive Fibromatosis

SpringWorks Therapeutics Inc. focuses on clinical research in desmoid tumours and aggressive fibromatosis, with attention to disease control in adults affected by these locally aggressive soft-tissue tumours.

Desmoid tumour
Aggressive fibromatosis
Soft-tissue tumour

Its research activity in this area includes therapeutic development for tumour-related symptoms and functional impairment associated with fibrotic growth.

Neurofibromatosis Type 1 and Plexiform Neurofibromas

The sponsor also invests in studies for neurofibromatosis type 1 and plexiform neurofibromas, including research relevant to paediatric patients with symptomatic or anatomically high-risk disease.

Neurofibromatosis type 1
Plexiform neurofibromas
Paediatric oncology

This area reflects a therapeutic interest in tumour burden, morbidity risk, and disease management across early-life and inherited tumour conditions.

Fibroproliferative and Rare Disease Therapeutics

SpringWorks Therapeutics maintains a research portfolio centred on fibroproliferative disorders and other rare diseases that require targeted oncologic and genetic-disease treatment strategies.

Fibroproliferative disorders
Rare tumours
Genetic disease

The funded trials involve conditions where tumour growth, tissue involvement, and long-term symptom burden are central therapeutic concerns.

Women’s Health and Ovarian Function

In adult women, the sponsor’s research includes attention to ovarian function and treatment-related reproductive effects in the context of desmoid tumour care.

Women’s health
Ovarian toxicity
Reproductive endocrinology

This area links tumour therapy with preservation and recovery of reproductive health in premenopausal patients.

Targeted Oncology and Pharmacology

The sponsor’s clinical research landscape includes targeted oncology and pharmacology, with studies examining treatment effects in both affected patients and healthy volunteers.